Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome.
The immunophenotype of peripheral blood blast cells was tested in 92 patients with acute myeloid leukemia (AML), who were diagnosed and treated at single centre, St Bartholomew's Hospital, from 1978-1987 with a standard adriamycin, cytosine arabinoside and 6-thioguanine regimen. Immunological analysis involved standard fluorescence flow cytometry and utilized 31 monoclonal antibodies to known myeloid antigens (of CD groups 11b, 11c, 13, 14, 15, 16, w17, 31, w32, 33, 34, 35 and 36), a number of relatively less well studied antibodies with potential specificity for AML, and a series of control antibodies to T and B lymphocytes, platelets, erythrocytes and of widespread distribution (CD45, leucocyte common; HLA-DR). The results highlighted a number of antibodies with wide myeloid reactivity, in addition to CD13 and 33 (present in 66 per cent and 76 per cent of cases, respectively), which may be of immunodiagnostic use. A number of correlations between AML cell immunophenotype and FAB morphology subtype were found; in particular five antibodies (CD11c, 10.1, Tu3, CD15 and CD16), of both predominant granulocytic and monocytic reactivity, reacted with cells of AML-M5 subtype (p less than 0.05). There was no significant correlation between immunophenotype and clinical and pathological features at presentation. Correlation with clinical outcome was not a prominent feature, in contrast to some reports based on multicentre data. However, of particular note was the strong association between early death (at less than 2 months) and the coexpression of Leucocyte Function Associated (LFA) antigens, CD11b and 11c, on patient's blast cells (p = 0.003). The relationship was independent of clinical features and persisted even if AML-M5 cases were excluded. The significance of this latter finding is unclear, but may be related to the known role of CD11b and 11c LFA antigens in the cellular response to infection.
Tucker
J
J
Department of Medical Oncology, St Bartholomew's Hospital, London, U.K.
Dorey
E
E
Gregory
W M
WM
Simpson
A P
AP
Amess
J A
JA
Lister
T A
TA
Horton
M A
MA
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D000943:Antigens, Differentiation / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016167:Integrin alphaXbeta2; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000175:diagnosis* / Q000276:immunology; D016177:Macrophage-1 Antigen; D008875:Middle Aged; D011379:Prognosis; D016028:Receptors, Leukocyte-Adhesion / Q000032:analysis; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D015214:Antigens, Differentiation, Myelomonocytic; D000951:Antigens, Neoplasm; D006684:HLA-DR Antigens; D016167:Integrin alphaXbeta2; D016177:Macrophage-1 Antigen; D016028:Receptors, Leukocyte-Adhesion